Recruiting | Phase III
Testing the Addition of the Antibody Atezolizumab to Usual Chemotherapy after Surgery in Patients with Colon Cancer
The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.
Group 1: Chemotherapy plus atezolizumab for 6 months, then atezolizumab alone for 6 months
Group 2: Chemotherapy for 6 months
Quality of Life surveys
After completion of the study patients will be followed for 8 years
Key Participation Requirements:
Male or Female
19 years and older
Stage III Colon cancer
Stage III colon cancer that has been removed by surgery.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.
To learn more about this clinical trial please contact us today!